Aug 12th 2011 - Edison Investment Research today published a report on EpiCept Corporation entitled "Poised For Growth". In summary, the report says:
Lead product Ceplene is being launched in the EU for the maintenance of remission and prevention of relapse of Acute Myeloid Leukaemia (AML). EpiCept has applied for an FDA SPA for the US Phase III trial. EpiCept is seeking a licensing partner to conduct Phase III trials of AmiKet for neuropathic pain. EpiCept also has two novel oncology products in Phase II trials for anaplastic thyroid cancer and glioblastoma multiforme and melanoma brain metastases; the latter product is licensed to Myrexis.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »